BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2014

View Archived Issues

Telik seeks shareholder approval of proposals to transition to MabVax Therapeutics

Read More

Delay to Pernix's acquisition of U.S. Treximet rights

Read More

MediciNova reports data for MN-001 from advanced NASH mouse model

Read More

Ampio Pharmaceuticals reports data from open-label portion of osteoarthritis study

Read More

NeuroDerm's ND-0612H eligible for EMA's centralized procedure

Read More

IntelliCell BioSciences files pre-IND with FDA for osteoarthritis study

Read More

Galapagos delivers second drug candidate in osteoarthritis alliance with Servier

Read More

Anti-T-cell receptor MAb investigated for inducing immunotherapeutic potential

Read More

Novel human anti-CD83 MAb shows potential for GVHD

Read More

New LPA1 receptor antagonists prepared at InterMune

Read More

Jazz Pharmaceuticals completes acquisition of rights to defibrotide in the Americas

Read More

Focus on Ebola: New strategies in discovery and design of therapies against the lethal disease

Read More

HMG-1 identified as an early biomarker of functional recovery after kidney transplantation

Read More

Polish scientists patent new helquat derivatives for cancer

Read More

Cannabis Science begins preclinical studies on cannabinoid formulations in neurological diseases

Read More

Scientists at Roche and Genentech design new DLK inhibitors for neurodegenerative disorders

Read More

Galapagos synthesizes new JAK inhibitors

Read More

Cytori Therapeutics provides update on ATHENA trials

Read More

Aurigene Discovery Technologies reports new Nampt inhibitors

Read More

NanoString Technologies receives approval in Australia for breast cancer assay

Read More

E.U. approves Roche's Avastin for platinum-resistant recurrent ovarian cancer

Read More

Eisai reflects on accomplishments of first quarter of fiscal 2014

Read More

MMRGlobal to grant royalty-free licenses to universities to research Ebola therapies

Read More

Oxford Immunotec acquires Boulder Diagnostics assets

Read More

Boehringer Ingelheim returns PGE2 inhibitor program to Orexo

Read More

CTI BioPharma's pacritinib receives FDA fast track status for myelofibrosis

Read More

FDA approves oritavancin for acute bacterial skin and skin structure infections

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 4, 2025.
  • Illustration of chromosome unraveling down to the DNA

    First phase of synthetic human genome project successfully completes

    BioWorld
    The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • 3D Euro symbol

    Laigo raises €11.5M seed money for targeted protein degradation

    BioWorld Science
    Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing